{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:06:05Z","timestamp":1787069165219,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00277-023-05588-6","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T01:01:23Z","timestamp":1704934883000},"page":"1979-1987","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study"],"prefix":"10.1007","volume":"103","author":[{"given":"Shuang","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingtong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4958-2489","authenticated-orcid":false,"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"5588_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11899-020-00568-3","volume":"15","author":"MH Jagosky","year":"2020","unstructured":"Jagosky MH, Usmani SZ (2020) Extramedullary Disease in Multiple Myeloma. Curr Hematol Malig Rep 15:62\u201371","journal-title":"Curr Hematol Malig Rep"},{"key":"5588_CR2","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJM199706053362307","volume":"336","author":"R Bataille","year":"1997","unstructured":"Bataille R, Harousseau JL (1997) Multiple myeloma. N Engl J Med 336:1657\u20131664","journal-title":"N Engl J Med"},{"key":"5588_CR3","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013e548","journal-title":"Lancet Oncol"},{"key":"5588_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.blre.2019.04.002","volume":"36","author":"S Sevcikova","year":"2019","unstructured":"Sevcikova S, Minarik J, Stork M et al (2019) Extramedullary disease in multiple myeloma - controversies and future directions. Blood Rev 36:32\u201339","journal-title":"Blood Rev"},{"key":"5588_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","volume":"34","author":"M Bhutani","year":"2020","unstructured":"Bhutani M, Foureau DM, Atrash S et al (2020) Extramedullary multiple myeloma. Leukemia 34:1\u201320","journal-title":"Leukemia"},{"key":"5588_CR6","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2013.094409","volume":"99","author":"L Pour","year":"2014","unstructured":"Pour L, Sevcikova S, Greslikova H et al (2014) Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica 99:360\u2013364","journal-title":"Haematologica"},{"key":"5588_CR7","first-page":"890","volume":"103","author":"N Gagelmann","year":"2018","unstructured":"Gagelmann N, Eikema DJ, Iacobelli S et al (2018) Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica 103:890\u2013897","journal-title":"Haematologica"},{"key":"5588_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/bjh.13382","volume":"169","author":"C Varga","year":"2015","unstructured":"Varga C, Xie W, Laubach J et al (2015) Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol 169:843\u2013850","journal-title":"Br J Haematol"},{"key":"5588_CR9","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","volume":"97","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Heuck C, Mitchell A et al (2012) Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica 97:1761\u20131767","journal-title":"Haematologica"},{"key":"5588_CR10","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/ajh.25579","volume":"94","author":"I Avivi","year":"2019","unstructured":"Avivi I, Cohen YC, Suska A et al (2019) Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. Am J Hematol 94:1132\u20131140","journal-title":"Am J Hematol"},{"key":"5588_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/bjh.12223","volume":"161","author":"L Billecke","year":"2013","unstructured":"Billecke L, Murga Penas EM, May AM et al (2013) Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol 161:87\u201394","journal-title":"Br J Haematol"},{"key":"5588_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/ejh.12377","volume":"93","author":"HJ Shin","year":"2014","unstructured":"Shin HJ, Kim K, Lee JW et al (2014) Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma. Eur J Haematol 93:414\u2013421","journal-title":"Eur J Haematol"},{"key":"5588_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/ejh.12688","volume":"97","author":"L Besse","year":"2016","unstructured":"Besse L, Sedlarikova L, Greslikova H et al (2016) Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol 97:93\u2013100","journal-title":"Eur J Haematol"},{"key":"5588_CR14","first-page":"2663","volume":"125","author":"YY Lai","year":"2012","unstructured":"Lai YY, Huang XJ, Cai Z et al (2012) Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China. Chin Med J (Engl) 125:2663\u20132670","journal-title":"Chin Med J (Engl)"},{"key":"5588_CR15","doi-asserted-by":"publisher","first-page":"e1132","DOI":"10.1634\/theoncologist.2019-0132","volume":"24","author":"X Li","year":"2019","unstructured":"Li X, Chen W, Wu Y et al (2019) 1q21 gain combined with high-risk factors is a heterogeneous prognostic factor in newly diagnosed multiple myeloma: a multicenter study in China. Oncologist 24:e1132\u2013e1140","journal-title":"Oncologist"},{"key":"5588_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","volume":"11","author":"TM Schmidt","year":"2021","unstructured":"Schmidt TM, Fonseca R, Usmani SZ (2021) Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J 11:83","journal-title":"Blood Cancer J"},{"key":"5588_CR17","doi-asserted-by":"crossref","unstructured":"Garifullin A, Voloshin S, Shuvaev V et al (2019) Significance of modified risk stratification Msmart 3.0 and autologous stem cell transplantation for patients with newly diagnosed multiple myeloma. Blood 134:5593\u20135593","DOI":"10.1182\/blood-2019-130092"},{"key":"5588_CR18","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00277-021-04475-2","volume":"100","author":"Y Jin","year":"2021","unstructured":"Jin Y, Yu X, Du J et al (2021) The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma. Ann Hematol 100:1251\u20131260","journal-title":"Ann Hematol"},{"key":"5588_CR19","doi-asserted-by":"crossref","unstructured":"Hanamura I (2021) Gain\/amplification of chromosome arm 1q21 in multiple myeloma. Cancers (Basel) 13(2):256","DOI":"10.3390\/cancers13020256"},{"key":"5588_CR20","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","volume":"116","author":"BA Walker","year":"2010","unstructured":"Walker BA, Leone PE, Chiecchio L et al (2010) A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 116:e56-65","journal-title":"Blood"},{"key":"5588_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","volume":"132","author":"L Rasche","year":"2018","unstructured":"Rasche L, Angtuaco EJ, Alpe TL et al (2018) The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood 132:59\u201366","journal-title":"Blood"},{"key":"5588_CR22","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.26639","volume":"97","author":"E Kastritis","year":"2022","unstructured":"Kastritis E, Migkou M, Dalampira D et al (2022) Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications. Am J Hematol 97:1142\u20131149","journal-title":"Am J Hematol"},{"key":"5588_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.leukres.2010.05.002","volume":"35","author":"H Chang","year":"2011","unstructured":"Chang H, Trieu Y, Qi X et al (2011) Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: adverse effect of 1q21 gains. Leuk Res 35:95\u201398","journal-title":"Leuk Res"},{"key":"5588_CR24","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412\u20133420","journal-title":"J Clin Oncol"},{"key":"5588_CR25","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S et al (2015) Revised international staging system for multiple myeloma: a Report from International Myeloma Working Group. J Clin Oncol 33:2863\u20132869","journal-title":"J Clin Oncol"},{"key":"5588_CR26","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328\u2013e346","journal-title":"Lancet Oncol"},{"key":"5588_CR27","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4110\/in.2017.17.4.250","volume":"17","author":"K Batsukh","year":"2017","unstructured":"Batsukh K, Lee SE, Min GJ et al (2017) Distinct clinical outcomes between paramedullary and extramedullary lesions in newly diagnosed multiple myeloma. Immune Netw 17:250\u2013260","journal-title":"Immune Netw"},{"key":"5588_CR28","doi-asserted-by":"crossref","unstructured":"Blad\u00e9 J, Fern\u00e1ndez de Larrea C, Rosi\u00f1ol L et al (2011) Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 29:3805\u20133812","DOI":"10.1200\/JCO.2011.34.9290"},{"key":"5588_CR29","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1097\/PAS.0000000000001459","volume":"44","author":"Y Liu","year":"2020","unstructured":"Liu Y, Jelloul F, Zhang Y et al (2020) Genetic basis of extramedullary plasmablastic transformation of multiple myeloma. Am J Surg Pathol 44:838\u2013848","journal-title":"Am J Surg Pathol"},{"key":"5588_CR30","first-page":"321","volume":"13","author":"G Tricot","year":"2005","unstructured":"Tricot G, Rasmussen E, Anaissie E et al (2005) Total therapy 2 (TT2) for Multiple Myeloma (MM): Thalidomide (T) effects superior Complete Response (CR) and Event-Free Survival (EFS); similar Overall Survival (OS) linked to shorter post-relapse survival. J Promot Manag 13:321\u2013337","journal-title":"J Promot Manag"},{"key":"5588_CR31","doi-asserted-by":"crossref","unstructured":"Janjetovic S, Lohneis P, Nogai A, Balci D, Rasche L, J\u00e4hne D, Bokemeyer C, Schilling G, Blau IW, Schmidt-Hieber M (2021) Clinical and biological characteristics of medullary and extramedullary plasma cell dyscrasias. Biology (Basel) 10(7):629","DOI":"10.3390\/biology10070629"},{"key":"5588_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106793","volume":"115","author":"S Gao","year":"2022","unstructured":"Gao S, Li Q, Dong F et al (2022) Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: a retrospective study. Leuk Res 115:106793","journal-title":"Leuk Res"},{"issue":"Suppl 1","key":"5588_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/10245330512331390140","volume":"10","author":"J Shaughnessy","year":"2005","unstructured":"Shaughnessy J (2005) Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 10(Suppl 1):117\u2013126","journal-title":"Hematology"},{"key":"5588_CR34","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/ni.2527","volume":"14","author":"V Peperzak","year":"2013","unstructured":"Peperzak V, Vikstr\u00f6m I, Walker J et al (2013) Mcl-1 is essential for the survival of plasma cells. Nat Immunol 14:290\u2013297","journal-title":"Nat Immunol"},{"key":"5588_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107660","volume":"31","author":"S Nourreddine","year":"2020","unstructured":"Nourreddine S, Lavoie G, Paradis J et al (2020) NF45 and NF90 regulate mitotic gene expression by competing with Staufen-mediated mRNA decay. Cell Rep 31:107660","journal-title":"Cell Rep"},{"key":"5588_CR36","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1038\/s41388-020-1222-7","volume":"39","author":"SQ Luo","year":"2020","unstructured":"Luo SQ, Xiong DH, Li J et al (2020) C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma. Oncogene 39:3354\u20133366","journal-title":"Oncogene"},{"key":"5588_CR37","first-page":"295","volume":"9","author":"W Yu","year":"2016","unstructured":"Yu W, Guo R, Qu X et al (2016) The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population. Onco Targets Ther 9:295\u2013302","journal-title":"Onco Targets Ther"},{"key":"5588_CR38","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bbmt.2009.11.025","volume":"16","author":"P Nemec","year":"2010","unstructured":"Nemec P, Zemanova Z, Greslikova H et al (2010) Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant 16:548\u2013554","journal-title":"Biol Blood Marrow Transplant"},{"key":"5588_CR39","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1182\/bloodadvances.2019000702","volume":"3","author":"A Slomp","year":"2019","unstructured":"Slomp A, Moesbergen LM, Gong JN et al (2019) Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. Blood Adv 3:4202\u20134214","journal-title":"Blood Adv"},{"key":"5588_CR40","doi-asserted-by":"publisher","first-page":"14671","DOI":"10.1038\/s41598-021-93835-z","volume":"11","author":"E Kriegova","year":"2021","unstructured":"Kriegova E, Fillerova R, Minarik J et al (2021) Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities. Sci Rep 11:14671","journal-title":"Sci Rep"},{"key":"5588_CR41","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","volume":"4","author":"N Abdallah","year":"2020","unstructured":"Abdallah N, Greipp P, Kapoor P et al (2020) Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv 4:3509\u20133519","journal-title":"Blood Adv"},{"key":"5588_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24375","volume":"36","author":"YT Wang","year":"2022","unstructured":"Wang YT, Bao L, Chu B et al (2022) Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis. J Clin Lab Anal 36:e24375","journal-title":"J Clin Lab Anal"},{"key":"5588_CR43","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/leu.2011.204","volume":"26","author":"KD Boyd","year":"2012","unstructured":"Boyd KD, Ross FM, Chiecchio L et al (2012) A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 26:349\u2013355","journal-title":"Leukemia"},{"key":"5588_CR44","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1182\/blood-2013-12-546077","volume":"123","author":"JR Sawyer","year":"2014","unstructured":"Sawyer JR, Tian E, Heuck CJ et al (2014) Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. Blood 123:2504\u20132512","journal-title":"Blood"},{"key":"5588_CR45","doi-asserted-by":"crossref","unstructured":"Tang HKK, Fung CY, Morgan GJ et al (2022) The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain. Ther Adv Hematol 13:20406207221082044","DOI":"10.1177\/20406207221082043"},{"key":"5588_CR46","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875\u20131883","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05588-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05588-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05588-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T03:07:50Z","timestamp":1715569670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05588-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["5588"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05588-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]},"assertion":[{"value":"1 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were performed in accordance with the ethical standards established in the Declaration of Helsinki and its later amendments. This study was approved by the Ethics Committee of the Peking University Third Hospital (2021665).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"The requirement for informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}